medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2017, Number 09

<< Back Next >>

Ginecol Obstet Mex 2017; 85 (09)

Comparison of automated platforms for the HPV genotypification

Calva-Espinosa DY, Campos-Romero A, Moreno-Camacho JL, Meza-Castro MC, Canizalez-Román VA, Alcántar-Fernández J

Language: Spanish
References: 25
Page: 569-577
PDF size: 358.31 Kb.


ABSTRACT

Objetive: To compare operative performance and concordance of human papillomavirus genotyping results obtained on Cobas® 4800 and BD Viper™ LT automated systems from liquid-based cytology samples.
Materials and Methods: Retrospective study in 1964 women attending the clinics of Salud Digna para todos I.A.P. from April to June 2016 to perform the Papanicolaou study; samples were stored in the BD SurePath™ liquid-based cytology collectors. The Cobas® 4800 and BD Viper™ LT systems were used for virus genotyping. The results were analyzed with the Pearson χ2 test, and concordance was obtained using the Cohen Kappa index.
Results: 1934 of liquid-based cytology samples were analyzed on the Cobas® 4800 and BD Viper™ LT platforms. The concordance between the results obtained by both platforms was very high (κ = 0.832). Moreover, there are differences between the number of positive and negative results reported, as well as in the proportions of the different genotypes, however, these were not statistically significant.
Conclusion: There are no significant differences between the results obtained for the detection of the human papillomavirus obtained by the Cobas® 4800 and BD Viper™ LT platforms. However, at the operational level, there are important differences that must be taken into account when implementing any of these platforms.


REFERENCES

  1. Papilomavirus humanos (PVH) y cáncer cervicouterino. Nota descriptiva N° 380 Marzo de 2015 (OMS). Consulta en Octubre de 2016. http://www.who.int/mediacentre/ factsheets/fs380/es/

  2. Asiaf A, Ahmad ST, Mohammad SO, Zargar MA. Review of the current knowledge on the epidemiology, pathogenesis, and prevention of human papillomavirus infection. Eur J Cancer Prev. 2014 May;23(3):206-24.

  3. Information Centre on HPV and cancer (HPV Information Centre), 2016. Human papillomavirus and related diseases report. http://www.hpvcentre.net/statistics/reports/ XWX.pdf

  4. Comité Nacional del Cancer en la Mujer, Posicionamiento del Subgrupo de Expertos. Utilización de las pruebas de biología molecular en la detección temprana del cáncer cérvico-uterino.

  5. http://cnegsr.salud.gob.mx/contenidos/descargas/CancerdelaMujer/ Comite/PosicionamientoSubgrupo.pdf

  6. Programa de Acción Específico. Prevención y Control del Cáncer de la Mujer. 2013-2018. Consultada en Octubre de 2016. http://www.cnegsr.salud.gob.mx/contenidos/Programas_ de_Accion/cancermama/ProgAccionCancer.html

  7. Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, Solomon D, Wentzensen N, Lawson HW. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2013 Apr; 17(5 Suppl 1):S1-S27.

  8. Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJ, Arbyn M, Kitchener H, Segnan N, Gilham C, Giorgi-Rossi P, Berkhof J, Peto J, Meijer CJ. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomized controlled trials. Lancet. 2014 Feb 8; 383(9916):524-32.

  9. Lazcano-Ponce E, Lörincz AT, Salmerón J, Fernández I, Cruz A, Hernández P, Mejia I, Hernández-Avila M. A pilot study of HPV DNA and cytology testing in 50,159 women in the routine Mexican Social Security Program. Cancer Causes Control. 2010 Oct;21(10):1693-700.

  10. Lazcano-Ponce E, Lorincz AT, Cruz-Valdez A, Salmerón J, Uribe P, Velasco-Mondragón E, Nevarez PH, Acosta RD, Hernández-Avila M. Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial. Lancet. 2011 Nov 26; 378(9806):1868-73.

  11. Wright TC Jr, Stoler MH, Behrens CM, Apple R, Derion T, Wright TL. The ATHENA human papillomavirus study: design, methods, and baseline results. Am J Obstet Gynecol. 2012 Jan;206(1):46.e1-46.e11.

  12. Wright TC Jr, Stoler MH, Sharma A, Zhang G, Behrens C, Wright TL; ATHENA (Addressing THE Need for Advanced HPV Diagnostics) Study Group. Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV+ cytology-negative results. Am J Clin Pathol. 2011 Oct; 136(4):578-86.

  13. Stoler MH, Wright TC Jr, Sharma A, Apple R, Gutekunst K, Wright TL; ATHENA (Addressing THE Need for Advanced HPV Diagnostics) HPV Study Group. High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am J Clin Pathol. 2011 Mar; 135(3):468-75.

  14. Torres-Ibarra L, Lazcano-Ponce E, Franco EL, Cuzick J, Hernández- Ávila M, Lorincz A, Rivera B, Ramírez P, Mendiola- Pastrana I, Rudolph SE, León-Maldonado L, Hernández R, Barrios E, Gravitt P, Moscicki AB, Schmeler KM, Flores YN, Méndez-Hernández P, Salmerón J; FRIDA Study Group. Triage strategies in cervical cancer detection in Mexico: methods of the FRIDA Study. Salud Publica Mex. 2016 Apr; 58(2):197-210.

  15. Einstein MH, Martens MG, Garcia FA, Ferris DG, Mitchell AL, Day SP, Olson MC. Clinical validation of the Cervista HPV HR and 16/18 genotyping tests for use in women with ASCUS cytology. Gynecol Oncol. 2010 Aug 1; 118(2):116-22.

  16. Whitlock EP, Vesco KK, Eder M, Lin JS, Senger CA, Burda BU. Liquid-based cytology and human papillomavirus testing to screen for cervical cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2011 Nov 15; 155(10):687-97.

  17. Else EA, Swoyer R, Zhang Y, Taddeo FJ, Bryan JT, Lawson J, Van Hyfte I, Roberts CC. Comparison of real-time multiplex humanpapillomavirus (HPV) PCR assays with INNO- LiPA HPV genotyping extra assay. J Clin Microbiol. 2011 May; 49(5):1907-12.

  18. Cuzick J, Cadman L, Mesher D, Austin J, Ashdown-Barr L, Ho L, Terry G, Liddle S, Wright C, Lyons D, Szarewski A. Comparing the performance of six human papillomavirus test in a screening population. Br J Cancer. 2013 Mar 5; 108(4):908-13.

  19. The Netherlands is the first country to transition its national cervical cancer screening program from Pap to primary HPV screening. https://global.hpv16and18.com/netherlands- HPV-primary-screening

  20. The American Cancer Society guidelines for the prevention and early detection of cervical cancer. http://www. cancer.org/cancer/cervicalcancer/moreinformation/ cervicalcancerpreventionandearlydetection/cervicalcancer- prevention-and-early-detection-cervical-cancerscreening- guidelines

  21. Georgalis L, de Sanjosé S, Esnaola M, Bosch FX, Diaz M. Present and future of cervical cancer prevention in Spain: a cost-effectiveness analysis. Eur J Cancer Prev. 2016 Sep; 25(5):430-9.

  22. Park JS, Namkoong SE, Han SK, Nha DJ, Lee HY, Kim SJ. Comparison of L1 consensus primers with E6 type specific primers for detection of human papillomaviruses in paraffin sections of cervical neoplasia. J Korean Med Sci. 1993 Feb; 8(1):60-7.

  23. Morris BJ. Cervical human papillomavirus by PCR: advantages of targeting the E6/E7 region. Clin Chem Lab Med. 2005; 43(11):1171-7.

  24. Cricca M1, Morselli-Labate AM, Venturoli S, Ambretti S, Gentilomi GA, Gallinella G, Costa S, Musiani M, Zerbini M. Viral DNA load, physical status and E2/E6 ratio as a marker to grade HPV16 positive women for high-grade cervical lesions. Gynecol Oncol. 2007 Sep; 106(3):549-57.

  25. Doorbar J. Papillomavirus life cycle organization and biomarker selection. Dis markers. 2007; 23(4):297-313.




2020     |     www.medigraphic.com